Optimal molecular selection to benefit from nivolumab-ipilimumab in clear-cell renal cell carcinoma

Yann-Alexandre Vano1, Réza Elaidi2, Letuan Phan2

  • 1Department of Medical Oncology, Hoôpital Europeéen Georges Pompidou, Institut du Cancer Paris CARPEM, AP-HP Centre-Université Paris Cité, 75015 Paris, France (Y-AV, SO); Centre de Recherche des Cordeliers, INSERM, Université Paris Cité, Sorbonne Université, F-75006, Paris, France; INSERM U970, PARCC, 75015 Paris, France.

The Lancet. Oncology
|June 30, 2022
PubMed
Abstract

No abstract available in PubMed .

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K